The deal, which merged Mahopac National Bank with Sleepy Hollow Bancorp, closed Friday.

The six Sleepy Hollow banks, in Pleasantville, Ossining, Yonkers and Sleepy Hollow, are now known as Mahopac National Bank’s Sleepy Hollow Division, said Tompkins, based in Ithaca.

The merger created a regional banking subsidiary with $750 million in assets and 15 branches in Westchester, Putnam and Dutchess counties, Tompkins said.

The organizations, which have a satellite office in Tarrytown, provide services to those with epilepsy and developmental disabilities.

The groups were previously housed in the Blue Hill office tower in Pearl River.

Jean Barda, an imaging industry veteran, will lead the association’s efforts in Europe to promote growth of and establishes standards for photographic equipment such as lenses in cell phones and other electronic gear, said I3A, based in White Plains.

An expert in imaging and display processes, Barda has registered a dozen patents, some of which are still used in TV production, such as multilingual captioning, I3A said.

Barda also served on the group’s board and its predecessor organization, DIG, for six years, I3A said.

In other business, shareholders re-elected nine of 10 board members on its board of directors, the Harrison-based defense contractor said.

Raymond LeBoeuf, an ITT director since 2000, is retiring from the board and didn’t stand for re-election.

Shareholders also approved Deloitte & Touche LLP as the company’s independent auditor, ITT said.

In afternoon trading, shares of the company were down a fraction to $66.43 a share.

The Eastview-based biotechnology company said Friday it was notified two days prior that it hadn’t yet regained compliance with a regulation that requires the company’s shares to maintain a market value of $35 million for 10 consecutive trading days.

Last month, Nasdaq officials gave EpiCept until May 5 to regain compliance with the listing requirement.
With last week’s news, EpiCept said it plans to seek a hearing with Nasdaq officials.

EpiCept shares also face delisting for failing to maintain a minimum $1 a share bid price, Nasdaq officials warned the company last month. The company. which is developing treatments for pain and cancer, has until Oct. 13 to regain compliance with minimum-bid price rules.

In the event the company’s shares are delisted, EpiCept said, they may be eligible to trade on the over-the-counter market, an informal method for trading stocks.

“This is a very competitive market, and I knew that the best way to serve my clients and associates was to join a bigger team with more resources,” said Bill Vrooman, Nelson Vrooman founder and chief executive.

Vrooman, along with Nelson Vrooman President Mike Graessle, will join Prudential Rand as associate brokers, Prudential Rand said.

The deal, the terms of which weren’t disclosed, makes Prudential Rand the largest real-estate firm in White Plains, the New City-based company said.

As part of the transaction, Nelson Vrooman’s offices at 709 Westchester Ave. will close and combine with those of Prudential Rand at 1 N. Broadway.

The deal will also result in the transfer of 20 Nelson Vrooman workers to Prudential Rand, which has 20 offices in the Hudson Valley.

The loss widened from the $10.4 million, or 40 cents a share, reported for last year’s first quarter, the company said this morning.
Revenues dropped to $14.8 million from $17.6 million.

Most of the revenue came from reimbursements Progenics got from drug giant Wyeth for work Progenics did developing a drug under an agreement the company’s have.

The U.S. Food and Drug Administration last month approved the company’s application to market Relistor for patients on pain medications for advanced illnesses. Some of those pain medications cause constipation that cannot be relieved with laxatives.
Progenics is also testing a drug for the treatment of the AIDS virus.

The company, the parent of Barr Laboratories Inc., earned $23 million, or 21 cents a share, in the quarter that ended in March. A year earlier, the company earned $12 million, or 11 cents a share.

On an adjusted basis that does not comply with generally accepted accounting principles, the company earned 57 cents a share, down from 73 cents last year.

Revenues were $608 million, up from $597 million.

Bruce L. Downey, the company’s chairman and chief executive, said: “While our results for the first quarter did not meet our expectations, we believe that these results will improve in the second half of the year and demonstrate the value of expanding our operations and markets outside the U.S.”

He said the company had strong sales in Germany, Russia and Poland.

A year earlier, the company earned $1.4 million, or 2 cents a share.

The company, which markets Rawlings sporting goods, Mr. Coffee machines and Coleman camping equipment, also reported its results on a basis that does not comply with general accepted accounting principles. On that basis, Jarden’s adjusted net income was $16.5 million, or 22 cents a share, compared with $17.1 million, or 24 cents a share, last year.

“While the first quarter is traditionally Jarden’s seasonally smallest quarter, our performance was in line with our expectations and a good start to achieving our full-year outlook,” Martin E. Franklin, the company’s chairman and chief executive, said in a statement.

He said the poor economy is hurting consumer confidence and retail sales, but the company’s Outdoor Solutions segment still grew its sales by 3.6 percent on a comparable basis.

On a per-share basis, the company lost 13 cents during this year’s quarter, the third quarter of its fiscal 2008. A year earlier, the loss was 4 cents a share.

This year’s results included $3.2 million in one-time expenses, including a provision for obsolete inventory, a provision for possible legal settlements and costs associated with the resignation of former chief executive Paul Intlekofer, the company said this morning.

Revenues dropped to $10.8 million, from $15.8 million. Revenues in last year’s quarter included a large one-time sale of Selenomax High Selenium Yeast. Without that sale, revenues would have been $13.2 million.